IDEAYA Biosciences (IDYA) Long-Term Investments (2019 - 2026)
IDEAYA Biosciences (IDYA) posted Long-Term Investments of $301.7 million for Q1 2026, down 26.46% sequentially from $410.3 million in Q4 2025, and down 15.88% YoY from $358.7 million in Q1 2025.
IDEAYA Biosciences (IDYA) Long-Term Investments (2019 - 2026) Analysis & Trends
IDEAYA Biosciences has reported Long-Term Investments for 8 years, with the latest figure at $301.7 million in Q1 2026.
- Quarterly Long-Term Investments fell 15.88% year-over-year to $301.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $301.7 million (down 15.88% YoY) and the FY2025 annual result came in at $410.3 million, up 1.1% from the prior year.
- Long-Term Investments fell to $301.7 million in Q1 2026 per IDYA's latest filing, from $410.3 million in the prior quarter.
- Over five years, Long-Term Investments peaked at $410.3 million in Q4 2025 and troughed at $7.7 million in Q3 2022.
- A 5-year average of $192.1 million and a median of $242.6 million in 2024 frame the typical range for Long-Term Investments.
- The sharpest annual moves came in 2022 and 2024: Long-Term Investments slumped 93.66% in 2022, then soared 1966.75% in 2024.
- Over 5 years, Long-Term Investments stood at $8.3 million in 2022, then jumped by 1192.44% to $107.5 million in 2023, then soared by 277.55% to $405.8 million in 2024, then rose by 1.1% to $410.3 million in 2025, then dropped by 26.46% to $301.7 million in 2026.
- According to Business Quant data, Long-Term Investments over the past three periods registered $301.7 million, $410.3 million, and $350.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 372.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.17 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | IDEAYA Biosciences | 3.50 Bn | 2.67 Bn | - | 413.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 413.93 Mn |
| Mar 31, 2026 | 301.71 Mn |
| Dec 31, 2025 | 410.30 Mn |
| Sep 30, 2025 | 349.96 Mn |
| Jun 30, 2025 | 322.13 Mn |
| Mar 31, 2025 | 358.67 Mn |
| Dec 31, 2024 | 405.83 Mn |
| Sep 30, 2024 | 280.13 Mn |
| Jun 30, 2024 | 251.07 Mn |
| Mar 31, 2024 | 242.64 Mn |
| Dec 31, 2023 | 107.49 Mn |
| Sep 30, 2023 | 42.39 Mn |
| Jun 30, 2023 | 16.38 Mn |
| Mar 31, 2023 | 11.74 Mn |
| Dec 31, 2022 | 8.32 Mn |
| Sep 30, 2022 | 7.69 Mn |
| Jun 30, 2022 | 55.17 Mn |
| Mar 31, 2022 | 93.63 Mn |
| Dec 31, 2021 | 121.29 Mn |
| Sep 30, 2021 | 121.22 Mn |